Ken Walsh has been appointed to the scientific advisory board of Health Discovery Corporation, a biotechnology company focused on biomarker and pathway discovery for diagnostic markers and drug targets. Welsh is currently a professor of clinical genomics at Royal Brompton Hospital and Imperial College in London. He is also a science advisor to the West London Transplant Center, and a visiting professor at Oxford University and the University of Utrecht. He received a BSc, PhD and DSc from Newcastle University.